Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00927199
Other study ID # B2007:071
Secondary ID
Status Completed
Phase Phase 2
First received June 17, 2009
Last updated January 31, 2013
Start date September 2007
Est. completion date June 2008

Study information

Verified date January 2013
Source University of Manitoba
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of high-oleic canola oil and a high-oleic canola/flaxseed oil blend as compared to a typical Western diet on plasma lipids, fatty acid profiles, and risk factors associated with cardiovascular disease in hypercholesterolemic patients. Furthermore, the metabolism of dietary oleic acid and alpha-linolenic acid contained in high-oleic canola oil and flaxseed oil will be investigated.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Fasting serum LDL-Cholesterol >3.0 mmol/L

- Body mass index (BMI) between 22-36 kg/m2

Exclusion Criteria:

- smoking

- use of lipid lowering therapy

- documented cardiovascular/atherosclerotic disease

- inflammatory disease

- diabetes

- uncontrolled hypertension

- kidney disease

- other systemic diseases

- cancer

- chronic alcohol consumption (> 2 servings/day)

- excessive exercise expenditure (> 4000 kcal/week)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Intervention

Dietary Supplement:
High-Oleic Canola Oil
Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
High-Oleic Canola/Flaxseed Oil Blend
Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
Western Dietary Control
Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))

Locations

Country Name City State
Canada Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Winnipeg Manitoba

Sponsors (4)

Lead Sponsor Collaborator
University of Manitoba Agri-Food Research and Development Initiative, Canola Council of Canada, Flax Canada 2015 Inc.

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Gillingham LG, Gustafson JA, Han SY, Jassal DS, Jones PJ. High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects. Br J Nutr. 2011 Feb;105(3):417-27. doi: 10.1017/S0007114510003697 — View Citation

Gillingham LG, Harding SV, Rideout TC, Yurkova N, Cunnane SC, Eck PK, Jones PJ. Dietary oils and FADS1-FADS2 genetic variants modulate [13C]a-linolenic acid metabolism and plasma fatty acid composition. Am J Clin Nutr. 2013 Jan;97(1):195-207. doi: 10.3945 — View Citation

Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011 Mar;46(3):209-28. doi: 10.1007/s11745-010-3524-y. Epub 2011 Feb 10. Review. — View Citation

Gillingham LG, Robinson KS, Jones PJ. Effect of high-oleic canola and flaxseed oils on energy expenditure and body composition in hypercholesterolemic subjects. Metabolism. 2012 Nov;61(11):1598-605. doi: 10.1016/j.metabol.2012.04.016. Epub 2012 Jun 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serum Lipids Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase No
Primary Inflammatory Biomarkers: C-Reactive Protein, Interleukin-6, sE-Selectin, sVCAM-1, sICAM-1 Study Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase No
Primary Intima-Medial Thickness by Carotid Ultrasound Study Baseline (during Day 1-3) and Endpoint (during Day 24-26) of each experimental phase No
Primary Energy Expenditure by Indirect Calorimetry Study Baseline (during Week 1) and Endpoint (during Week 4) of each experimental phase No
Primary Body Composition by Dual Emission X-Ray Absorptiometry (DEXA) Baseline (Day1,2) and Endpoint (Day 28,29) of each experimental phase No
Primary Oxidation and Conversion of U-13C-Alpha Linolenic Acid Day 27 (time 0-8 hrs), Day 28 (24 hrs), Day 29 (48 hrs) of each experimental phase No
Primary Plasma Fatty Acid Concentrations Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase No
Secondary Arterial Stiffness Index by Pulse Wave Analysis Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment